The Lundquist Institute
Antony Hoarau - PhD is a postdoctoral fellow at The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center since October 2022. Previously, Antony completed a PhD at Inserm, focusing on hyaluronic acid and bronchial inflammation in cystic fibrosis from October 2018 to June 2022. Antony also gained research experience through two master's internships at Université de Reims Champagne-Ardenne, studying the influences of different matrikines on extracellular vesicle release in colorectal cancer and the effects of the QS-13 peptide on angiogenesis in vitro. Early research included amplification of the Suc2 gene and identification of bacterial strains through molecular techniques. Antony holds a Master's degree in Biology Health Quality, specializing in cellular and molecular biology, as well as a Bachelor's degree in Biochemistry and Environmental Biology.
This person is not in any teams
The Lundquist Institute
The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), is an engine of innovation with a global reach and a 67-year reputation of improving and saving lives. With its new medical research building, its state-of-the-art incubator, “BioLabs at The Lundquist,” existing laboratory and support infrastructure, and a 15-acre tech park in the planning stages, The Lundquist Institute is poised to serve as a hub for the Los Angeles area’s burgeoning biotech scene. The research institute has over 100 principal investigators (PhDs, MDs, and MD/PhDs) working on more than 600 research studies, including therapies for numerous orphan diseases, and is responsible for three FDA-approved drugs including the first approved treatment for sickle cell disease in 20 years.